• Epidemiology and Risk Factors
• 41 min
  1. The changing prevalence of asthma

  • Dr. Deborah Jarvis
• 29 min
  2. Recent advances in asthma genetics

  • Prof. Miriam Moffatt
• 35 min
  3. Asthma: an epidemic caused by epigenetics?

  • Prof. David Schwartz
• 30 min
  4. Role of the microbiota in asthma

  • Prof. B. Brett Finlay
• 32 min
  5. Diet and asthma

  • Prof. Lewis Smith
• 43 min
  6. Obesity and asthma

  • Prof. Anne Dixon
• 35 min
  7. Occupational asthma: management beyond the textbooks

  • Prof. Paul Cullinan
• Clinical Phenotypes
• 42 min
  8. The origins of asthma

  • Prof. Peter Sly
• 46 min
  9. Pre-school wheeze

  • Prof. Andrew Bush
• 50 min
  10. Updates on the management of difficult asthma in school-aged children

  • Prof. Andrew Bush
• 24 min
  11. Smoking asthmatics

  • Prof. Neil Thomson
• 27 min
  12. Aspirin exacerbated respiratory disease

  • Prof. Chris Corrigan
• Mechanisms of Asthma
• 48 min
  13. Advances in asthma: airway inflammation

  • Prof. William Busse
• 48 min
  14. The role of mast cells in asthma

  • Prof. Peter Bradding
• 67 min
  15. Dendritic cells in asthma

  • Prof. Bart Lambrecht
• 30 min
  16. The airway smooth muscle in asthma

  • Prof. Judith Black
• 49 min
  17. Role of virus infection in asthma 1

  • Prof. Sebastian Johnston
• 27 min
  18. Role of virus infection in asthma 2

  • Prof. Sebastian Johnston
• 51 min
  19. Severe asthma: characterisation, mechanisms & treatment

  • Prof. Fan Chung
• 46 min
  20. Steroid resistance in asthma: mechanisms and potential therapies

  • Prof. Ian Adcock
• 26 min
  21. Macrophage in asthma

  • Prof. Douglas Robinson
• Diagnosis of Asthma
• 70 min
  22. Physiology of asthma and involvement of small airways

  • Prof. Charles G. Irvin
• 27 min
  23. Induced sputum in asthma

  • Prof. Antonio Spanevello
• 61 min
  24. Advances in asthma: the role of exhaled nitric oxide in the assessment and management of asthma

  • Prof. Robin Taylor
• Therapy and Management
• 41 min
  25. Pulmonary drug delivery

  • Prof. Anthony J. Hickey
• 32 min
  26. The management of chronic asthma

  • Prof. Mark Fitzgerald
• 21 min
  27. Inhaled corticosteroids and beta2-agonists

  • Dr. Omar S. Usmani
• 20 min
  28. Management of "difficult asthma"

  • Prof. Elisabeth Bel
• 47 min
  29. Management of acute exacerbations of asthma

  • Dr. Chris Fanta
• 34 min
  30. Non-pharmacological treatments for asthma

  • Prof. Neil Thomson
• 45 min
  31. Asthma: beyond the prescription

  • Prof. Martyn Partridge
• 45 min
  32. New drugs for asthma

  • Prof. Peter Barnes
• 24 min
  33. Anti-IgE therapy for asthma

  • Dr. Andrew Menzies-Gow
• Archived Lectures *These may not cover the latest advances in the field
• 45 min
  34. New drugs for asthma

  • Prof. Peter Barnes
• 35 min
  35. Asthma phenotypes in children

  • Prof. Andrew Bush
• 40 min
  36. Steroid resistance in asthma: mechanisms and potential therapies

  • Prof. Ian Adcock
• 42 min
  37. Severe asthma in children

  • Prof. Andrew Bush

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Aspirin
3. Aspirin-exacerbated respiratory disease (AERD)
4. What we know about AERD
5. AERD before and after sensitization
6. Segmental lysine aspirin challenge
7. Urinary LTE4 after aspirin
8. Urinary LTE4
9. Excess cysteinyl leukotrienes
10. Genetic regulation of LTC4 synthase activity
11. Cysteinyl leukotriene receptors
12. Airways responsiveness to LTE4
13. AERD involvement in LTE4 abnormalities
14. Outline of eicosanoid metabolism (1)
15. Bronchial mucosal LTC4 synthase expression
16. AERD and prostanoids
17. Outline of eicosanoid metabolism (2)
18. PGE2 and leukotriene inhibition (1)
19. Inhaled PGE2 abrogates bronchospasm
20. Inhaled PGE2 increases in urinary LTE4
21. Other effects of PGE2
22. PGE2 and leukotriene inhibition (2)
23. Airways COX-1 expression in asthma
24. Airways COX-2 expression in asthma
25. COX-2 inhibitors in aspirin sensitive asthma
26. Urinary LTE4 excretion following challenge
27. PGE2 and leukotriene inhibition (3)
28. PGE2 production by fibroblast lines (2-3 weeks)
29. PGE2 production by nasal epithelial lines (6 days)
30. PGE2 and leukotriene inhibition (4)
31. EP receptors expression
32. Hypothesis
33. CysLT1/2 and EP-1/2/3/4 receptors
34. Global submucosal staining
35. Immunoreactive inflammatory cells percentage
36. The EP2 receptor alone is immunomodulatory
37. Are there more LTE to be found?
38. Data replication
39. Biopsy stained with antibodies
40. Double immunohistochemistry
41. Results for EP1 and EP2
42. Results for EP3 and EP4
43. PGE2 and leukotriene inhibition (5)
44. Summary: what we know
45. Summary: what we still don't know
46. Collaborators
47. Thank you for your kind attention

Topics Covered

• Clinical features
• AERD as a disease of excessive leukotriene production
• Alterations in eicosanoid metabolism
• The protective role of Prostaglandin E2 (PGE2)
• Reduced PGE2 signalling as a mechanism for AERD
• The PGE2 receptor EP2 as a molecular target

Links

Series:

• Advances in Asthma

Categories:

• Biochemistry
• Cell Biology
• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on December 27, 2012
• Reviewed on April 12, 2022

Financial Disclosures

• Prof. Chris Corrigan has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.